|
Indonesia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Indonesia Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Indonesia.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Indonesian pharmaceutical and healthcare industry.
Competitive intelligence, Indonesian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Indonesian market.
The Indonesia Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Indonesia Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Indonesian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Indonesia to test other views – a key input for successful budgeting and strategic business planning in the Indonesian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Indonesian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Indonesia.
- Exploit The Latest Competitive Indonesian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Indonesia.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Indonesia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Indonesia Pharmaceutical And Healthcare Industry SWOT |
| Indonesia Political SWOT |
| Indonesia Economic SWOT |
| Indonesia Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ranking |
| Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q209 |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Indonesia – Market Overview |
| Regulatory Regime |
| Intellectual Property Issues |
| Generic Drug Legislation |
| Labelling Requirements |
| Counterfeit And Substandard Drugs |
| Free Trade Agreements |
| Pricing Regime |
| Reimbursement Regime |
| Price Cuts |
Chapter - Industry Trends And Developments |
| Epidemiology |
| Table: UN Millennium Development Goals |
| Avian Flu |
| International Avian Flu Partnerships |
| Healthcare System |
| Healthcare System Reform |
| International Healthcare Collaborations |
| Pharmaceutical Sector |
| Recent Pharmaceutical Industry Developments |
| Pharmaceutical Retail Sector |
| Research And Development |
| Herbal Medicines |
| Medical Devices |
| Table: Indonesia – Medical Device Market Forecast |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Indonesia – Drug Expenditure Indicators, 2003-2013 |
| Key Growth Factors – Industry |
| Table: Indonesia – Health Expenditure Indicators, 2003-2013 |
| Key Growth Factors – Macroeconomic |
| Table: Indonesia - Economic Activity |
| Prescription Market Forecasts |
| Table: Indonesia – Prescription Market Indicators, 2003-2013 (IDRmn unless otherwise stated) |
| Patented Market Forecast |
| Table: Indonesia – Patented Drug Market Indicators, 2003-2013 |
| Generics Market Forecast |
| Table: Indonesia – Generic Drug Market, 2003-2013 (IDRmn unless otherwise stated) |
| OTC Market Forecast |
| Table: Indonesia – OTC Drug Market, 2003-2013 |
| Export/Import Forecast |
| Table: Indonesia – Pharmaceutical Trade Indicators, 2003-2013 (US$mn) |
| Medical Devices Market Forecast |
| Table: Indonesia – Medical Device Market Indicators, 2004-2013 (US$mn unless otherwise stated) |
| Other Healthcare Data And Forecasts |
| Table: Indonesia – Other Health Indicators, 2003-2013 |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Table: Indonesia's Pharmaceutical Market Landscape (Q406) |
Chapter - Company Profiles |
| Leading Foreign Manufacturers |
| Sanofi-Aventis |
| Pfizer |
| Novartis |
| GlaxoSmithKline |
| Merck & Co |
| Bayer |
| Indigenous Manufacturers |
| PT Kalbe Farma |
| PT Bio Farma |
| Kimia Pharma |
| PT SidoMuncul |
| Combiphar PT |
| Darya-Varia |
Chapter - Country Snapshot: Indonesia Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2000-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2010 (US$) |
| Table: Average Annual Manufacturing Wages, 2000-2012 (IDR) |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Indonesia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Indonesia is one of the most promising long-term opportunities for pharmaceutical companies. However, numerous short-term challenges must be overcome, such as protectionist government and inequitable access to healthcare. The value of pharmaceuticals sold in 2008 reached US$2.79bn and BMI is forecasting a compound annual growth rate (CAGR) of 11.85% through 2013.
In February 2009 it was revealed that the Indonesian government would give IDR300bn (US$24.7mn) to local drugmakers who had been hard hit by the volatile prices of raw materials and intense pressure from rivals operating from low-cost bases. In return for the subsidy and an accelerated registration process, pharmaceutical companies must produce more affordable generic drugs. Health Minister Siti Fadilah Supari said, 'The programme will enable the national pharmaceutical industry to deal with the crisis.' This development was the first time a government had bailed out its pharmaceutical industry in the midst of the global financial downturn.
Highlighting its status as a leading Muslim nation, Indonesia announced in December 2008 that it would increase the value of medicine donations to Palestinians in Gaza from IDR2bn (US$167,000) to IDR10bn (US$835,000). The government said it would send domestically-manufactured medicines with a value of IDR300mn (US$25,000) and distribute IDR10bn to purchase more drugs in Egypt. This gesture is highly significant because Indonesia is struggling to provide its own citizens with affordable pharmaceuticals.
Despite being a highly religious country, ‘morning after’ pills are freely available in certain parts of Indonesia without a prescription. The Food and Drugs Monitoring and Counselling Team (TP2MO) were instructed in February 2009 to monitor the sales of the pills, which retail for IDR200,000 (US$16.73). However, given that TP2MO only carry out monitoring twice a year, an effective crackdown is unlikely in the short term.
Healthcare sector reform is underway, but challenges are numerous. In December 2008, it was revealed that some hospitals – both private and public – had been caught refusing treatment to patients on low incomes or those using the Public Health Assurance Programme (Jamkesmas). Those that restrict service will face ‘sanctions’. All hospital care in the Indonesia is free of charge for low-income families. However, patients must sign up for the public health insurance program in their locality.
|
Indonesia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |